{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:40:08Z","timestamp":1780555208168,"version":"3.54.1"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":632,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2000,4]]},"abstract":"<jats:sec><jats:title>Aim:<\/jats:title><jats:p>To compare the efficacy and gastrointestinal (GI) safety of nabumetone with two comparator non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs), diclofenac SR and piroxicam.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Two randomized, double\u2010blind, multicentre, parallel group trials were carried out in patients with moderate to severe osteoarthritis of the hip or knee. During the 6\u2003month treatment phase, the safety and efficacy of nabumetone (1500\u20132000\u2003mg\/day) was compared to diclofenac SR (100\u2003mg\/day) or piroxicam (20\u201330\u2003mg\/day). GI safety was evaluated by reviewing all adverse events reported during the trials and presenting all cases of ulcers (complicated and uncomplicated), as well as other bleeding events that may have been associated with NSAID administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Most of the efficacy parameters showed no significant differences between the NSAIDs, although diclofenac SR was significantly better than nabumetone in one of 18 efficacy parameters. Nabumetone\u2010treated patients experienced significantly fewer ulcer and bleeding events compared to patients treated with the comparator NSAIDs [1.1% (4\/348) vs. 4.3% (15\/346), <jats:italic>P<\/jats:italic>= 0.01]. Bleeding events, including outright upper or lower GI bleeding or a significant decline in haemoglobin, occurred in significantly fewer patients treated with nabumetone than with the comparator NSAIDs [1.1% (4\/348) vs. 3.5% (12\/346), <jats:italic>P\u2003<\/jats:italic>&lt;\u20030.05]. More importantly, complications associated with either ulcers (perforation) or bleeding (leading to hospitalization or withdrawal) occurred in significantly fewer patients receiving nabumetone [0% (0\/348)] than with comparator NSAIDs [1.4% (5\/346), (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.05)].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The results suggest that nabumetone was similar in efficacy by most criteria to diclofenac SR and piroxicam in relieving the symptoms of osteoarthritis; however, nabumetone\u2019s GI safety profile was generally superior to that of both comparator NSAIDs. In the pooled analysis, nabumetone was associated with a significantly lower total incidence of ulcers and bleeding events, and a significantly lower incidence of complications associated with these events.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2000.00715.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:41:05Z","timestamp":1047354065000},"page":"443-452","source":"Crossref","is-referenced-by-count":19,"title":["Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety"],"prefix":"10.1111","volume":"14","author":[{"family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780311118"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198904000-00009"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199000405-00003"},{"key":"e_1_2_6_5_2","first-page":"S3","article-title":"Nonsteroidal anti\u2010inflammatory drug safety: a view from the ARAMIS data bank","volume":"8","author":"Fries J.","year":"1996","journal-title":"Curr Opinion Rheumatol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00276-9"},{"key":"e_1_2_6_7_2","first-page":"924","article-title":"The American College of Gastroenterology bleeding registry: Preliminary findings","volume":"92","author":"Peura DA","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90018-T"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018832902287"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01303169"},{"key":"e_1_2_6_11_2","first-page":"32","article-title":"Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis","volume":"19","author":"Fleischmann RM.","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90608-5"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90391-2"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90392-3"},{"key":"e_1_2_6_15_2","first-page":"48","article-title":"Worldwide safety experience with nabumetone","volume":"19","author":"Bernhard GC.","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02668031"},{"key":"e_1_2_6_17_2","first-page":"S115","article-title":"Comparative toxicity of NSAIDs","volume":"40","author":"Singh G","year":"1997","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7119.1333"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1982.tb04796.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1994.tb01987.x"},{"key":"e_1_2_6_21_2","first-page":"270","article-title":"Interaction between nabumetone\u2014a new non\u2010steroidal anti\u2010inflammatory\u2014and the haemostatic system ex vivo","volume":"20","author":"Al Balla S","year":"1990","journal-title":"Haemostasis"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80039-8"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.16.4.494"},{"key":"e_1_2_6_24_2","first-page":"915","article-title":"A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis","volume":"22","author":"Bellamy N","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199000405-00007"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259402"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90390-B"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02113942"},{"key":"e_1_2_6_29_2","first-page":"6","article-title":"NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal","volume":"18","author":"Fries JF.","year":"1991","journal-title":"J Rheumatol"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(97)80048-0"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-4-257"},{"key":"e_1_2_6_32_2","first-page":"283","article-title":"The effect of diclofenac on platelet aggregation and post\u2010operative bleeding","volume":"2","author":"Francis JL","year":"1988","journal-title":"Hematol Rev"},{"key":"e_1_2_6_33_2","first-page":"161","article-title":"Effect of single dose of piroxicam on human platelet aggregation in vivo","volume":"1","author":"DiPerri T","year":"1979","journal-title":"Int J Tiss React"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00715.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00715.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2000.00715.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T13:20:16Z","timestamp":1698585616000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2000.00715.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["10.1046\/j.1365-2036.2000.00715.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00715.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,4]]}}}